Decreased tumoral hyaluronan content is accompanied by an increase in the hyaluronan degrading enzyme, hyaluronidase 2 (HYAL2), and a decrease in HAS1 and HAS2 expression in invasive melanomas and lymph node metastases compared to benign nevi and in situ melanomas [16]. The gene discussed is HYAL2; the disease is melanoma.